ZOLPIMIST
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZOLPIMIST (ZOLPIMIST).
Zolpidem is a nonbenzodiazepine hypnotic that binds selectively to the benzodiazepine type 1 (BZ1) receptor on the alpha1 subunit of the GABA-A chloride ion channel complex, potentiating the inhibitory effects of GABA.
| Metabolism | Primarily metabolized by CYP3A4 and CYP1A2 (minor), with contributions from CYP2C9 and CYP2D6. |
| Excretion | Renal (primarily as conjugated metabolites, approximately 80-85% of total clearance), fecal (approximately 10-15%), biliary (minor, <5%). |
| Half-life | Terminal elimination half-life is 2.8-3.2 hours in healthy adults. In elderly patients or those with hepatic impairment, half-life may be prolonged to 4-6 hours. |
| Protein binding | Approximately 92-95%, primarily to albumin. |
| Volume of Distribution | 0.8-1.3 L/kg, indicating extensive tissue distribution and penetration into the central nervous system. |
| Bioavailability | Oral: 30-40% (due to first-pass metabolism). Sublingual: 60-75%. Intranasal: 70-85%. |
| Onset of Action | Oral: 15-30 minutes (sublingual formulation: 5-10 minutes). Intranasal: 10-15 minutes. |
| Duration of Action | Oral: 3-4 hours (clinical sedation persists for 1-2 hours, residual effects for up to 6 hours). |
5 mg orally once daily at bedtime, maximum 10 mg/day.
| Dosage form | SPRAY, METERED |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (GFR <30 mL/min) due to lack of data. |
| Liver impairment | Child-Pugh A: 5 mg once daily. Child-Pugh B: 2.5 mg once daily. Child-Pugh C: not recommended. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | Initiate at 2.5 mg once daily at bedtime, maximum 5 mg/day due to increased sensitivity and risk of falls. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZOLPIMIST (ZOLPIMIST).
| Breastfeeding | Zolpidem is excreted into human breast milk. The milk-to-plasma ratio (M/P) is approximately 0.03-0.1, indicating low transfer. However, peak milk concentrations occur within 2-3 hours after maternal dose. Breastfeeding is generally not recommended during zolpidem therapy due to potential infant sedation and impaired feeding. If used, advise to avoid breastfeeding for at least 6 hours after dose to minimize exposure. |
| Teratogenic Risk | Zolpidem (ZOLPIMIST) is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects at high doses, but adequate human studies are lacking. First trimester: Possible increased risk of congenital malformations, though data are limited. Second and third trimesters: Risk of fetal exposure to CNS depressant effects, including hypotonia, respiratory depression, and withdrawal symptoms in neonates after chronic use. Late third trimester use may lead to neonatal sedation and floppy infant syndrome. |
■ FDA Black Box Warning
BOXED WARNING: Complex sleep behaviors including sleep-driving, sleepwalking, and other activities while not fully awake have been reported. Discontinue immediately if such behaviors occur.
| Serious Effects |
["History of complex sleep behaviors after taking zolpidem","Hypersensitivity to zolpidem or any component of the formulation","Use in combination with alcohol or other CNS depressants is not recommended (relative)"]
| Precautions | ["Complex sleep behaviors (e.g., sleep-driving, sleepwalking) – discontinue immediately if occur","CNS depressant effects – impaired alertness and motor coordination; risk of next-day impairment","Worsening of depression or suicidal ideation","Abuse and dependence potential – use with caution in patients with history of substance abuse","Respiratory depression - use with caution in patients with compromised respiratory function"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs, level of sedation, and respiratory rate. Assess fetal heart rate and uterine activity as per routine obstetric care. In neonates exposed near term, monitor for signs of respiratory depression, hypotonia, feeding difficulties, and withdrawal symptoms (irritability, tremors) for at least 48 hours postpartum. Consider prolonged monitoring in cases of high maternal dose or chronic use. |
| Fertility Effects | Limited data in humans. In animal studies, zolpidem did not significantly impair fertility at clinically relevant doses. However, CNS depressant effects may affect libido and sexual function. No specific fertility impairment has been documented in clinical use. |